A 10 mins at home test of COVID-19 may help detect asymptomatic carriers

Written By :  Dr. Kamal Kant Kohli
Published On 2020-10-02 04:21 GMT   |   Update On 2020-10-02 09:53 GMT

Caltech researchers have developed a new type of multiplexed test with a low-cost sensor that may enable the at-home diagnosis of a COVID infection in less than 10 minutes.The test may be carried out on small volumes of saliva or blood. The test doesn't require the involvement of a medical professional.A major hurdle in curbing the spread of COVID-19 pandemic is inability to...

Login or Register to read the full article

Caltech researchers have developed a new type of multiplexed test with a low-cost sensor that may enable the at-home diagnosis of a COVID infection in less than 10 minutes.

The test may be carried out on small volumes of saliva or blood. The test doesn't require the involvement of a medical professional.

A major hurdle in curbing the spread of COVID-19 pandemic is inability to identify asymptomatic carriers.The carrier of the virus might feel perfectly well and go about their daily business--taking the virus with them to work, to the home of a family member, or to public gatherings.Therefore there is global effort is the development of tests that can rapidly identify infections in people who are not yet symptomatic.

The research has been published online and will appear in the December issue of the journal Matter.

The research was conducted in the lab of Wei Gao, assistant professor in the Andrew and Peggy Cherng department of medical engineering.. Previously, Gao and his team have developed wireless sensors that can monitor conditions such as gout, as well as stress levels, through the detection of extremely low levels of specific compounds in blood, saliva, or sweat.

Gao's sensors are made of graphene, a sheet-like form of carbon. A plastic sheet etched with a laser generates a 3D graphene structure with tiny pores. Those pores create a large amount of surface area on the sensor, which makes it sensitive enough to detect, with high accuracy, compounds that are only present in very small amounts. In this sensor, the graphene structures are coupled with antibodies, immune system molecules that are sensitive to specific proteins, like those on the surface of a COVID virus, for example.

Previous versions of the sensor were impregnated with antibodies for the hormone cortisol, which is associated with stress, and uric acid, which at high concentrations causes gout. The new version of the sensor, which Gao has named SARS-CoV-2 RapidPlex, contains antibodies and proteins that allow it to detect the presence of the virus itself; antibodies created by the body to fight the virus; and chemical markers of inflammation, which indicate the severity of the COVID-19 infection.

"This is the only telemedicine platform I've seen that can give information about the infection in three types of data with a single sensor," Gao says. "In as little as a few minutes, we can simultaneously check these levels, so we get a full picture about the infection, including early infection, immunity, and severity."

Established COVID-testing technologies usually take hours or even days to produce results. Those technologies also require expensive, complicated equipment, whereas Gao's system is simple and compact.

So far, the device has been tested only in the lab with a small number of blood and saliva samples obtained for medical research purposes from individuals who have tested positive or negative for COVID-19. Though preliminary results indicate that the sensor is highly accurate, a larger-scale test with real-world patients rather than laboratory samples must be performed, Gao cautions, to definitively determine its accuracy.

With the pilot study now completed, Gao next plans to test how long the sensors last with regular use, and to begin testing them with hospitalized COVID-19 patients. Following in-hospital testing, he would like to study the suitability of the tests for in-home use. Following testing, the device will need to receive regulatory approval before it is available for widespread use at home.

"Our ultimate aim really is home use," he says. "In the following year, we plan to mail them to high-risk individuals for at-home testing. And in the future, this platform could be modified for other types of infectious disease testing at home."

Tags:    
Article Source : Journal matter

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News